1. Generics Bulletin
  2. >>Legal & IP

EU Firms Up Plans For Unitary Supplementary Protection Certificates

An Impact Assessment Is On The Way

 
• By Ian Schofield

A unified system for granting SPCs would significantly reduce the burden of seeking protection in up to 27 different EU countries, and would sit well alongside Europe's future unitary patent system, says the European Commission. It now preparing an impact assessment for the proposal.

IP concept
SPCs extend effective patent protection on pharmaceuticals • Source: Alamy

The European Commission has published details of its proposed centralized scheme for granting supplementary protection certificates with EU-wide validity that it says would cut costs and effort for innovators, offer more certainty to the off-patent pharmaceutical industry, and complement the future EU unitary patent scheme.

“This initiative aims to promote innovation and competitiveness in the EU, as well as to improve the healthcare system, by ensuring that the SPC system is fit for single market and digital age purposes, and that it becomes much more

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

More from Generics Bulletin